Factors influencing the SARS-CoV-2 infection and vaccination induced immune response in rheumatoid arthritis

Factors influencing the SARS-CoV-2 infection and vaccination induced immune response in rheumatoid arthritis

BackgroundTo investigate the factors that have significant impact on the Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) infection and vaccination induced immune response in rheumatoid arthritis (RA).MethodsSerological response was measured by quantifying anti-SARS-CoV-2 specific antib...

Full description

Bibliographic Details
Main Authors:	Dora Nemeth, Hajnalka Vago, Laszlo Tothfalusi, Zsuzsanna Ulakcsai, David Becker, Zsofia Szabo, Bernadett Rojkovich, Bela Merkely, Gyorgy Nagy
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-10-01
Series:	Frontiers in Immunology
Subjects:	COVID-19 rheumatoid arthritis antibody response T-cell response vaccination DMARD (disease-modifying antirheumatic drug treatment)
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.960001/full

Similar Items

T cell immune response predicts survival in severely ill COVID-19 patients requiring venovenous extracorporeal membrane oxygenation support
by: Zsuzsanna Ulakcsai, et al.
Published: (2023-08-01)

Immunological response and temporal associations in myocarditis after COVID-19 vaccination using cardiac magnetic resonance imaging: An amplified T-cell response at the heart of it?
by: Hajnalka Vago, et al.
Published: (2022-09-01)

Largely Accelerated Arterial Aging in Rheumatoid Arthritis Is Associated With Inflammatory Activity and Smoking in the Early Stage of the Disease
by: Nikolett Mong, et al.
Published: (2020-11-01)

Autoantibodies against complement factor B in rheumatoid arthritis
by: Alexandra T. Matola, et al.
Published: (2023-02-01)

Non-pharmacological treatment in difficult-to-treat rheumatoid arthritis
by: Judit Majnik, et al.
Published: (2022-08-01)

Biomarkers to Predict DMARDs Efficacy and Adverse Effect in Rheumatoid Arthritis
by: Kai Wei, et al.
Published: (2022-03-01)

Distinct In Vitro T-Helper 17 Differentiation Capacity of Peripheral Naive T Cells in Rheumatoid and Psoriatic Arthritis
by: Eszter Baricza, et al.
Published: (2018-04-01)

Pain, sleep and emotional well-being explain the lack of agreement between physician- and patient-perceived remission in early rheumatoid arthritis
by: Samina A. Turk, et al.
Published: (2018-06-01)

Ultrasound-detected bone erosion is a relapse risk factor after discontinuation of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis whose ultrasound power Doppler synovitis activity and clinical disease activity are well controlled
by: Shin-ya Kawashiri, et al.
Published: (2017-05-01)

Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
by: Mysler E, et al.
Published: (2021-06-01)

Editor’s Pick: JAK Inhibitors in the Treatment Algorithm of Rheumatoid Arthritis: A Review
by: Salvatore Bellinvia, et al.
Published: (2018-07-01)

Automated T1 and T2 mapping segmentation on cardiovascular magnetic resonance imaging using deep learning
by: András Kalapos, et al.
Published: (2023-07-01)

Impact of Clinical and Morphological Factors on Long-Term Mortality in Patients with Myocardial Bridge
by: György Bárczi, et al.
Published: (2022-04-01)

Advances in the implications of the gut microbiota on the treatment efficacy of disease-modifying anti-rheumatic drugs in rheumatoid arthritis
by: Junyu Fan, et al.
Published: (2023-09-01)

Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity
by: Juthamas Prawjaeng, et al.
Published: (2023-05-01)

Real-world treatment patterns for repository corticotropin injection in patients with rheumatoid arthritis
by: Howard Busch, et al.
Published: (2022-03-01)

Sustained Remission and Outcomes with Abatacept plus Methotrexate Following Stepwise Dose De-escalation in Patients with Early Rheumatoid Arthritis
by: Paul Emery, et al.
Published: (2023-03-01)

Proteomic Changes of Osteoclast Differentiation in Rheumatoid and Psoriatic Arthritis Reveal Functional Differences
by: Orsolya Tünde Kovács, et al.
Published: (2022-07-01)

Neutrophil-lymphocyte ratio, pain perception, and disease activity score may serve as important predictive markers for sustained remission in rheumatoid arthritis
by: S. Chandrashekara, et al.
Published: (2016-02-01)

Management of rheumatoid arthritis during pregnancy: challenges and solutions
by: Krause ML, et al.
Published: (2016-03-01)

Long-Term Safety, Efficacy, and Patient-Centered Outcomes of Filgotinib in the Treatment of Rheumatoid Arthritis: Current Perspectives
by: Tanaka Y, et al.
Published: (2023-10-01)

A Model to Predict Future Biologic or Targeted Synthetic DMARD Switch at a Subsequent Clinic Visit in Rheumatoid Arthritis
by: Laura C. Cappelli, et al.
Published: (2023-10-01)

Risk of cancer for patients with rheumatoid arthritis versus general population: a national claims database cohort studyResearch in context
by: Maxime Beydon, et al.
Published: (2023-12-01)

Rheumatoid Vasculitis, an Uncommon Complication of Non-Deforming Rheumatoid Arthritis: A Case Report
by: Taha ZI, et al.
Published: (2022-07-01)

Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region
by: Zoltán Kaló, et al.
Published: (2017-01-01)

Managing Disease-Modifying Antirheumatic Drugs (DMARDs) for Patients Undergoing Elective Spine Surgery: A Pilot Survey
by: James C. Mamaril-Davis, et al.
Published: (2024-01-01)

The clinical utility of musculoskeletal ultrasound for disease activity evaluation and therapeutic response prediction in rheumatoid arthritis patients: A narrative review
by: Chia-Ching Chen, et al.
Published: (2023-01-01)

Clinical evaluation of DMARDs and NSAIDs in cases of Rheumatoid arthritis in Chhattisgarh
by: Basant Kumar Maheshwari
Published: (2018-01-01)

Rheumatoid arthritis: current therapeutics compendium
by: Dariushnejad Hassan, et al.
Published: (2022-04-01)

Effect of immunomodulating treatment (usage of DMARDs) in rheumatoid arthritis on depression
by: Magdalena Kozyra, et al.
Published: (2020-08-01)

Iguratimod: Novel Molecular Insights and a New csDMARD for Rheumatoid Arthritis, from Japan to the World
by: Yuji Nozaki
Published: (2021-05-01)

Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis
by: Yinzhu Jin, et al.
Published: (2017-07-01)

The importance of early arthritis in patients with rheumatoid arthritis
by: Georgiana Iftimie, et al.
Published: (2018-10-01)

Clinical and Laboratory Associations with Methotrexate Metabolism Gene Polymorphisms in Rheumatoid Arthritis
by: Leon G. D’Cruz, et al.
Published: (2020-09-01)

CHALLENGES AND OPPORTUNITIES IN APPROACH THERAPY OF RHEUMATOID ARTHRITIS
by: Ângela Sequeira Silva, et al.
Published: (2013-06-01)

The use of biosimilars as a new approach to the treatment of rheumatoid arthritis
by: N. V. Chichasova, et al.
Published: (2021-08-01)

Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic Drugs
by: Alvin F. Wells, et al.
Published: (2019-05-01)

BIOlogical Factors that Limit sustAined Remission in rhEumatoid arthritis (the BIO-FLARE study): protocol for a non-randomised longitudinal cohort study
by: Fiona Rayner, et al.
Published: (2021-07-01)

Biological treatment and exercise as an alternative to typical rheumatoid arthritis therapy: pathophysiology and effects
by: Artur Aghadi, et al.
Published: (2023-02-01)

Patients With Rheumatoid Arthritis With an Inadequate Response to Disease‐Modifying Antirheumatic Drugs at a Higher Risk of Acute Coronary Syndrome
by: Chung‐Yuan Hsu, et al.
Published: (2021-04-01)